🇺🇸 FDA
Patent

US 11268077

Materials and methods for treatment of hemoglobinopathies

granted A61KA61K31/395A61K35/28

Quick answer

US patent 11268077 (Materials and methods for treatment of hemoglobinopathies) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/395, A61K35/28, A61K38/193, A61P